Annual Drug Patent Expirations for CAPLYTA
Caplyta is a drug marketed by Intra-cellular and is included in one NDA. It is available from two suppliers. There are eighteen patents protecting this drug.
Drug patent litigation for CAPLYTA.
This drug has one hundred and thirty-eight patent family members in twenty countries.
The generic ingredient in CAPLYTA is lumateperone tosylate. Two suppliers are listed for this compound. Additional details are available on the lumateperone tosylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
